Valneva (NASDAQ:VALN) Posts Earnings Results, Misses Estimates By $0.32 EPS

Valneva (NASDAQ:VALN) posted its earnings results on Wednesday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32), Zacks reports. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%.

Valneva Stock Up 4.9 %

Shares of NASDAQ VALN traded up $0.33 during trading on Thursday, reaching $7.06. 9,807 shares of the stock were exchanged, compared to its average volume of 25,911. The company has a market capitalization of $573.78 million, a price-to-earnings ratio of -55.00 and a beta of 1.93. The business’s 50-day moving average price is $6.24 and its 200 day moving average price is $5.60. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.